Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mIL-2 plasmid is a gene therapy construct consisting of a DNA plasmid vector encoding the murine Interleukin-2 (mIL-2) gene. It is designed to induce the expression and secretion of IL-2, a cytokine that plays a critical role in the activation and expansion of T cells and natural killer (NK) cells. In preclinical research, particularly for renal cell carcinoma (RCC), the plasmid is delivered via hydrodynamic gene delivery to stimulate a systemic or localized anti-tumor immune response. It has been investigated as a monotherapy and in combination with chemotherapy (such as 5-fluorouracil) or other cytokine-encoding plasmids (such as mIL-12) to enhance therapeutic efficacy against metastatic lesions in the liver, lung, and kidney.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mIL-2 plasmid.